Teva Pharmaceutical Industries Ltd. has moved ecopipam into US Food and Drug Administration Priority Review for pediatric Tourette syndrome, putting a first-in-class selective dopamine D1 receptor antagonist on course for a regulatory decision late in the first quarter of 2027 after a Phase 3 study showed a 53% reduction in the risk of tic relapse among children and adolescents who initially responded to treatment. If approved, ecopipam could introduce the first fundamentally new pharmacological mechanism for Tourette syndrome in decades rather than another medicine acting principally through dopamine D2 receptors.
FDA acceptance of a New Drug Application means the agency has determined that the filing is sufficiently complete for substantive review; it does not mean ecopipam has been approved or that the clinical evidence has already satisfied the statutory standard for marketing authorization. Priority Review shortens FDA’s review target for qualifying applications judged potentially capable of providing significant improvements in treatment, while the actual benefit-risk determination remains ahead.
The filing is supported by both a positive Phase 2b programme and a 216-participant Phase 3 study published in JAMA Neurology. That pivotal study used a randomized-withdrawal design rather than conventional parallel treatment from baseline, an important detail because the headline 53% risk reduction applies to patients who had already demonstrated a clinically meaningful response during an initial open-label ecopipam period.
How does ecopipam differ from established Tourette syndrome medicines?
Tourette syndrome is characterized by persistent motor and vocal tics beginning during childhood. Tic severity can fluctuate substantially over time and may be accompanied by conditions such as obsessive-compulsive symptoms or attention-deficit/hyperactivity disorder, creating considerable variation in how much individual patients are affected.
Behavioral intervention remains an important treatment option, while pharmacological approaches include alpha-2 adrenergic agonists and medicines that reduce dopamine D2 receptor signaling. D2-modulating therapies can be effective, but their use can be constrained by adverse effects including weight gain, metabolic abnormalities, sedation and drug-induced movement disorders.
Ecopipam takes a different approach by selectively antagonizing dopamine D1 receptors. Dopamine signaling involves several receptor subtypes, and D1 receptors have a distinct distribution and role within the neural circuits involved in motor behavior.
The rationale is not that dopamine D1 inhibition is universally better than D2 modulation, but that it may suppress tics through a different neurobiological pathway while potentially avoiding some adverse effects associated with conventional dopamine-blocking therapies.
That distinction could become commercially important if approval is followed by a safety profile capable of supporting longer-term pediatric treatment. Many Tourette syndrome patients are children or adolescents who may need pharmacological management through important periods of physical and neurological development, making weight, metabolism and involuntary movement effects particularly relevant.
Teva describes ecopipam, also known as EBS-101, as first-in-class. The medicine originated from Emalex Biosciences, whose acquisition by Teva gave the larger company control of the programme and its regulatory strategy.
What did the Phase 3 trial actually demonstrate?
The pivotal Phase 3 trial enrolled 216 people with Tourette syndrome across 77 sites in North America and Europe between January 2023 and February 2025. Of those participants, 167 were pediatric and 49 were adults.
Everyone initially received open-label ecopipam for 12 weeks. To qualify for randomized withdrawal, participants had to demonstrate at least a 25% improvement from baseline in the Yale Global Tic Severity Scale Total Tic Score at both weeks eight and 12.
This enrichment step is crucial for understanding the result. Of the 216 initially treated participants, only 104 entered the randomized double-blind period, including 90 pediatric patients and 14 adults. Participants who had demonstrated a response were randomized either to continue ecopipam or transition in masked fashion toward placebo for another 12 weeks.
The primary endpoint examined time to relapse among pediatric patients. Relapse was defined as losing at least half of the improvement previously achieved in tic score, starting additional Tourette syndrome medication or requiring hospitalization because symptoms worsened.
Among pediatric participants, 68.1% of those assigned to placebo relapsed compared with 41.9% of those continuing ecopipam. The resulting hazard ratio was 0.47, with a 95% confidence interval of 0.26 to 0.84 and a P value of 0.008. That represents a 53% relative reduction in the risk of relapse during the randomized phase.
Median time to relapse was four weeks in the placebo group, while median time could not be estimated in the ecopipam group because more than half of patients maintained their improvement through the study period.
When participants of all ages were analyzed together, the hazard ratio was also 0.47, with a P value of 0.005. The adult subgroup was far too small for definitive conclusions: only 14 adults entered the randomized period, and the adult analysis did not achieve statistical significance.
Why does the randomized-withdrawal design require careful interpretation?
Randomized-withdrawal trials can be useful when researchers want to determine whether a treatment effect persists and when prolonged placebo exposure is undesirable. They can also reduce the number of participants needed to demonstrate maintenance of efficacy because only known responders proceed into the randomized comparison.
The trade-off is generalizability.
Ecopipam’s Phase 3 trial does not show that 53% of every child beginning treatment will avoid relapse because of the medicine. It shows that among pediatric participants who first demonstrated a predefined response during 12 weeks of open-label treatment, continuing ecopipam reduced subsequent relapse risk compared with withdrawing active treatment.
That distinction becomes particularly relevant because a substantial portion of the original cohort did not advance to randomization.
Forty of the 216 enrolled participants discontinued during the open-label period because of lack of efficacy or inadequate therapeutic effect. Thirty-three discontinued because of adverse events, while other participants stopped for administrative or personal reasons.
Consequently, the pivotal study provides strong evidence of maintenance among responders, but it provides a less straightforward estimate of the average magnitude of benefit across every patient who might receive ecopipam after commercial launch.
The JAMA Neurology investigators explicitly identified this limitation, noting that responder-only randomization enriches the study population and that the design does not allow conventional estimation of the treatment-effect size across an unselected Tourette syndrome population.
That does not undermine the primary endpoint. It changes the clinical question the study answers.
What did Phase 3 show about weight gain, metabolic effects and movement disorders?
Safety could become one of ecopipam’s most important competitive attributes if FDA ultimately approves the therapy.
The Phase 3 investigators reported no signals for clinically relevant weight gain, adverse metabolic effects or drug-induced movement disorders during the study. These findings are relevant because such complications can limit existing dopamine-modulating therapies used for Tourette syndrome.
The study nevertheless provides only limited-duration evidence. Participants could receive ecopipam for up to 24 weeks across the open-label and randomized phases, which is sufficient to identify many common treatment-emergent events but not to characterize uncommon or very long-term safety risks.
Thirty-three of the 216 initially enrolled participants discontinued during the open-label phase because of adverse events, meaning the full FDA review will need to consider not only which adverse events occurred but their severity, frequency and relationship to treatment.
The eventual prescribing information, if ecopipam is approved, will provide a more definitive regulatory characterization of its safety profile.
Longer-term evidence is also available from an earlier open-label extension programme, but uncontrolled follow-up cannot replace post-marketing surveillance when a medicine begins reaching a substantially larger pediatric population.
Why could a D1 receptor drug change the Tourette syndrome treatment landscape?
The importance of ecopipam is partly historical.
Tourette syndrome pharmacotherapy has long relied on drugs acting through mechanisms developed originally for other neurological or psychiatric purposes rather than medicines designed around a distinct Tourette-specific pharmacological hypothesis.
Teva says ecopipam could become the first new treatment specifically indicated for pediatric Tourette syndrome in more than a decade and the first novel mechanism of action used for the disorder in more than 50 years.
A new mechanism does not automatically make a drug clinically superior, but it expands treatment choice in a disorder where response and tolerability vary substantially between patients.
Ecopipam could be particularly relevant for children who have clinically significant tics requiring pharmacological treatment but whose families or physicians are concerned about adverse metabolic or movement effects associated with other dopamine-modulating medicines.
The Phase 3 data also suggest that treatment effects extend across motor and phonic tics. Exploratory analyses favored continued ecopipam across several Yale Global Tic Severity Scale measures and clinician and caregiver assessments, although these analyses need to be interpreted within the enriched randomized-withdrawal design.
What will FDA have to decide before the 2027 action date?
The central regulatory question is whether the total evidence establishes a favorable benefit-risk profile for pediatric Tourette syndrome.
FDA will assess the Phase 3 maintenance-of-effect study alongside the earlier Phase 2b efficacy trial, longer-term safety information, manufacturing data, pharmacology and the proposed prescribing framework.
The agency will also have to determine how the randomized-withdrawal design should translate into labeling. Because patients first had to respond to open-label treatment before entering the pivotal randomized phase, regulators may scrutinize how efficacy is communicated to clinicians who will be initiating treatment in patients without knowing whether they will respond.
The application has Orphan Drug designation in addition to Priority Review, but neither regulatory designation predicts approval.
Teva’s targeted action date late in the first quarter of 2027 nevertheless creates a clear near-term decision point.
For the Tourette syndrome field, ecopipam has already accomplished something important scientifically: a selective D1 receptor antagonist has demonstrated maintenance of tic suppression in a randomized Phase 3 setting without the prominent metabolic or drug-induced movement signals historically associated with some existing therapies.
FDA must now determine whether that evidence is sufficient to turn a novel mechanism into a new pediatric treatment option.
